RESEARCH LETTER

MASLD and CMRFs: Combination or Separation? An Open Exploration From the Perspective of All-Cause Mortality

Zheng Li

Department of Radiation Oncology and Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China

Search for more papers by this author

Ting Luo,

Ting Luo

Institute of Breast Health Medicine, Department of Medical Oncology, Cancer Center, Breast Center, West China Hospital, Sichuan University, Chengdu, China

Search for more papers by this author

Dan Zheng,

Dan Zheng

Institute of Breast Health Medicine, Department of Medical Oncology, Cancer Center, Breast Center, West China Hospital, Sichuan University, Chengdu, China

Search for more papers by this author

Zhiping Li,

Zhiping Li

Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China

Search for more papers by this author

Dan Cao,

Corresponding Author

Dan Cao

[email protected]

orcid.org/0000-0003-2755-7258

Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China

Correspondence:

Dan Cao ([email protected])

Yue Hu ([email protected])

Search for more papers by this author

Yue Hu,

Corresponding Author

Yue Hu

[email protected]

orcid.org/0000-0002-7269-1301

Department of Paediatric Genetics, Endocrinology and Metabolism, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

Correspondence:

Dan Cao ([email protected])

Yue Hu ([email protected])

Search for more papers by this author

Zheng Li,

Zheng Li

Department of Radiation Oncology and Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China

Search for more papers by this author

Ting Luo,

Ting Luo

Institute of Breast Health Medicine, Department of Medical Oncology, Cancer Center, Breast Center, West China Hospital, Sichuan University, Chengdu, China

Search for more papers by this author

Dan Zheng,

Dan Zheng

Institute of Breast Health Medicine, Department of Medical Oncology, Cancer Center, Breast Center, West China Hospital, Sichuan University, Chengdu, China

Search for more papers by this author

Zhiping Li,

Zhiping Li

Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China

Search for more papers by this author

Dan Cao,

Corresponding Author

Dan Cao

[email protected]

orcid.org/0000-0003-2755-7258

Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China

Correspondence:

Dan Cao ([email protected])

Yue Hu ([email protected])

Search for more papers by this author

Yue Hu,

Corresponding Author

Yue Hu

[email protected]

orcid.org/0000-0002-7269-1301

Correspondence:

Dan Cao ([email protected])

Yue Hu ([email protected])

Search for more papers by this author

First published: 01 July 2025

https://doi.org/10.1111/liv.70212

Funding: This work was jointly supported by the National Natural Science Foundation of China, China (Grant No. 82272746), and the Medical Science and Technology Project of the Health Commission of Sichuan Province, China (Grant No. 21PJ135).

Zheng Li and Ting Luo contributed equally as co-first authors.

Share a link

Email
Wechat
Bluesky

No abstract is available for this article.

Conflicts of Interest

The authors declare no conflicts of interest.

Open Research

Data Availability Statement

The data that supports the findings of this study are available in the Supporting Information S1 of this article.

Supporting Information

References

1M. E. Rinella, J. V. Lazarus, V. Ratziu, et al., “A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature,” Journal of Hepatology 79 (2023): 1542–1556.
10.1016/j.jhep.2023.06.003
CAS PubMed Web of Science® Google Scholar
2G. Issa, Y. Shang, R. Strandberg, H. Hagström, and A. Wester, “Cause-Specific Mortality in 13,099 Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease in Sweden,” Journal of Hepatology (2025), https://doi.org/10.1016/j.jhep.2025.03.001.
10.1016/j.jhep.2025.03.001
Google Scholar
3M. Kwak, H. S. Kim, Z. G. Jiang, et al., “MASLD/MetALD and Mortality in Individuals With Any Cardio-Metabolic Risk Factor: A Population-Based Study With 26.7 Years of Follow-Up,” Hepatology 81 (2025): 228–237.
10.1097/HEP.0000000000000925
PubMed Web of Science® Google Scholar
4Z. M. Younossi, J. M. Paik, M. Stepanova, J. Ong, S. Alqahtani, and L. Henry, “Clinical Profiles and Mortality Rates Are Similar for Metabolic Dysfunction-Associated Steatotic Liver Disease and Non-Alcoholic Fatty Liver Disease,” Journal of Hepatology 80 (2024): 694–701.
10.1016/j.jhep.2024.01.014
CAS PubMed Web of Science® Google Scholar
5Y. B. Liang, X. Q. Ye, M. Pan, Y. Chen, Y. Yuan, and L. Luo, “Impact of Steatotic Liver Disease Subtypes, Sarcopenia, and Fibrosis on All-Cause and Cause-Specific Mortality: A 15.7-Year Cohort Study,” BMC Gastroenterology 25 (2025): 75.
10.1186/s12876-025-03661-0
PubMed Web of Science® Google Scholar
6J. Pustjens, L. A. van Kleef, H. L. A. Janssen, R. J. de Knegt, and W. P. Brouwer, “Differential Prevalence and Prognostic Value of Metabolic Syndrome Components Among Patients With MASLD,” JHEP Rep 6 (2024): 101193.
10.1016/j.jhepr.2024.101193
PubMed Web of Science® Google Scholar
7M. Li, W. Chen, Y. Deng, and W. Xie, “Impacts of Cardiometabolic Risk Factors and Alcohol Consumption on All-Cause Mortality Among MASLD and Its Subgroups,” Nutrition, Metabolism, and Cardiovascular Diseases 34, no. 9 (2024): 2085–2094.
10.1016/j.numecd.2024.05.018
CAS PubMed Web of Science® Google Scholar
8R. Oh, S. Kim, S. H. Cho, et al., “Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality,” Diabetes and Metabolism Journal 49 (2025): 80–91.
10.4093/dmj.2024.0042
PubMed Web of Science® Google Scholar
9C. K. Lo, D. Mertz, and M. Loeb, “Newcastle-Ottawa Scale: Comparing Reviewers' to Authors' Assessments,” BMC Medical Research Methodology 14, no. 45 (2014): 1–5.
PubMed Web of Science® Google Scholar
10M. B. Aboona, C. Faulkner, P. Rangan, et al., “Disparities Among Ethnic Groups in Mortality and Outcomes Among Adults With MASLD: A Multicenter Study,” Liver International 44 (2024): 1316–1328.
10.1111/liv.15880
PubMed Web of Science® Google Scholar

Volume45, Issue8

August 2025

e70212

MASLD and CMRFs: Combination or Separation? An Open Exploration From the Perspective of All-Cause Mortality

Conflicts of Interest

Open Research

Data Availability Statement

Supporting Information

References

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

MASLD and CMRFs: Combination or Separation? An Open Exploration From the Perspective of All-Cause Mortality

Conflicts of Interest

Open Research

Data Availability Statement

Supporting Information

References

References

Related

Information